Elsevier

Atherosclerosis

Volume 210, Issue 2, June 2010, Pages 569-574
Atherosclerosis

Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus

https://doi.org/10.1016/j.atherosclerosis.2009.12.007Get rights and content

Abstract

Background

Systemic lupus erythematosus (SLE) is associated with premature atherosclerosis but the mechanisms underlying this association are not understood. The role of endothelial dysfunction is hypothesized.

Methods

In predominantly non-Caucasian patients with SLE (N = 119) and controls (N = 71), carotid ultrasonography was performed and circulating endothelial cells (CECs), soluble endothelial protein C receptor and gene polymorphism at A6936G, soluble E-selectin (sE-selectin), and adiponectin were assessed.

Results

Carotid plaque was more prevalent among patients than controls (43% vs 17%, p = 0.0002). Mean CCA IMT was greater in patients compared to controls (0.59 ± 0.19 mm vs 0.54 ± 0.11 mm, p = 0.03). Among SLE patients, plaque was not associated with smoking, body-mass index, LDL, triglycerides, homocysteine, C-reactive protein, anti-ds DNA antibody, C3, C4, SLE activity, or medications. Age and levels of soluble E-selectin and adiponectin were significantly higher in the SLE patients with plaque compared to those without plaque in univariate and multivariate analyses. sE-selectin and adiponectin were found to serve as independent predictors of carotid plaque and that elevations were persistent over more than one visit. Unexpectedly, these biomarkers were present despite clinical quiescence.

Conclusion

Premature atherosclerosis is a consistent feature of SLE and extends across ethnicities. Higher levels of adiponectin may represent a physiological attempt to limit further endothelial damage already reflected by the elevation in sE-selectin and the observed increase in plaque represents overwhelming of this reparative process by atherogenic stimuli.

Introduction

Systemic lupus erythematosus (SLE) is a disease state posing several challenges to the clinician, including heterogeneity of presentation, undulating course, and an extraordinary risk for premature cardiovascular disease [1], [2]. Over two decades ago it was noted that the majority of deaths in patients with longer disease duration were attributed to atherosclerosis [1]. Indeed, the rate of myocardial infarction in women aged 35–44 years is 50 times greater than expected [2]. Patients with SLE have an increased atherosclerotic risk despite adjustment for traditional Framingham risk factors [2], [3]. Risk factors among SLE patients are somewhat controversial but may include longer duration of disease and lower likelihood of treatment with prednisone, cyclophosphamide, or hydroxychloroquine [4]. Thus, inflammation related to underlying disease is likely to be contributory. McMahon et al. have recently shown that plasma from SLE patients with premature atherosclerosis is enriched in proinflammatory HDL [5]. However, the inflammation may be clinically subtle since detectable cardiovascular events have been unexpectedly reported in SLE patients with extended periods of quiescence [6] and subclinical atherosclerosis has not correlated with disease activity index scores [4]. Thus, identification of biomarkers associated with atherogenic injury which might be present, independent of recognized lupus activity, should advance understanding of the pathology and guide prophylaxis for at risk subgroups.

The endothelium merits focus since it provides the physiologic boundary which limits extravasation and diapedesis of inflammatory cells. The generation of nitric oxide by the endothelium also promotes relaxation of the contractile elements of the smooth muscle of the arterial blood vessels. In atherogenic disease, endothelial protection is subverted perhaps because of a loss of boundary function via detachment of endothelial cells into the circulation and/or a change in the endothelial cell phenotype. Increased levels of circulating endothelial cells (CECs) have been observed in patients with active disease [7] and apoptotic CECs have been reported in SLE patients with diminished flow mediated dilatation (FMD) [8]. Soluble E-selectin (sE-selectin), likely shed from an abnormally activated endothelium, has been recently associated with atherosclerosis as defined by an abnormal coronary artery calcium assessed using electron beam computed tomography EBCT [9]. An integral membrane protein expressed on endothelial cells, endothelial protein C receptor (EPCR) has both anti-inflammatory and anti-thrombotic properties via its role in generating activated protein C. A recent study has linked increased atherosclerotic risk to shedding of the EPCR from the endothelial cell surface [10].

While these studies have highlighted the potential association of markers directly reflecting injury, absent is a focus on protective (anti-injury) molecules such as the adipocyte-derived protein, adiponectin. Germane to the consideration of protection is the relationship of adiponectin to atherosclerosis. Adiponectin, when elevated in peripheral blood is reported to promote a wide range of benefit at the site of blood vessel injury, such as the downregulation of adhesion molecules by attenuating the nuclear factor kB pathway [11], [12]. Adiponectin accumulates in the sub-endothelium of injured human arteries where it inhibits monocyte adhesion to endothelial cells and ultimately inhibits the migration and proliferation of vascular smooth muscle, which contributes to the atherosclerotic process [13]. In addition, adiponectin was found in blood vessel walls after experimental endothelial injury [14], and was strongly expressed around infarcted but not normal myocardium [15], supporting a role in vascular and endothelial remodeling.

Accordingly, this study was initiated to explore the endothelial contribution to cardiovascular risk in SLE. This was approached by evaluation of carotid ultrasonography in 119 SLE patients and 71 age and sex matched controls. An assessment of the endothelial contribution was made by evaluating a panel of biomarkers chosen to reflect pro- and anti-atherogenic injury.

Section snippets

Study population

This study and its informed consent form were approved by the Institutional Review Board of the New York University School of Medicine. During the period from August 2005 to July 2007, 119 patients were enrolled from the Lupus Clinic at the NYU-Hospital for Joint Diseases and the private practices of NYU physicians. All patients fulfilled at least four of the revised American College of Rheumatology criteria for the diagnosis of SLE [16]. Seventy-one healthy employees of the NYU Langone Medical

Comparison of patients with SLE and controls

The demographics of the 119 patients with SLE and 71 healthy controls are shown in Table 1. The cohort was ethnically diverse, including a minority of Caucasian subjects (41%). Hypertension was more common in SLE patients (36% vs 12% of controls; p = 0.0006). HDL and total cholesterol were lower in patients (patients vs controls; 57.2 mg/dL vs 63.6 mg/dL, p = 0.03; 177 mg/dL vs 188 mg/dL, p = 0.039, respectively), consistent with findings from prior studies [4]. There were no differences in LDL, TG,

Discussion

Premature atherosclerosis is a consistent feature of SLE and herein extends across all ethnicities. Carotid plaque was observed in over twice the proportion of lupus patients compared to age-, sex- and race/ethnicity-matched controls. Excess prevalence of plaque was seen beginning in the 5th decade of life. On multivariate analysis, age, SLE disease duration, sE-selectin, and adiponectin were the only independent predictors of plaque. Among lupus patients with plaque, elevations in these

Funding

This work was supported by a research grant to R.M.C. from the Lupus Research Institute, New York, NY. and by NIH/NCRR M01 RR0096. P.M.I. was supported by SLE Foundation, Inc. H.C. was supported by the Arthritis Foundation, New York Chapter.

Acknowledgements

We thank Drs. ER Gehrie, H Comerci, and E. Karis who worked on this project during their residencies/fellowships.

References (41)

  • M. McMahon et al.

    Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis

    Arthritis Rheum

    (2006)
  • R. Clancy et al.

    Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy

    Arthritis Rheum

    (2001)
  • Y.H. Rho et al.

    Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus

    J Rheumatol

    (2008)
  • H. Ireland et al.

    EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro

    Atherosclerosis

    (2005)
  • N. Ouchi et al.

    Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway

    Circulation

    (2000)
  • N. Ouchi et al.

    Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

    Circulation

    (1999)
  • M. Kumada et al.

    Association of hypoadiponectinemia with coronary artery disease in men

    Arterioscler Thromb Vasc Biol

    (2003)
  • Y. Okamoto et al.

    An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls

    Horm Metab Res

    (2000)
  • Y. Ishikawa et al.

    Changes in the distribution pattern of gelatin-binding protein of 28 kDa (adiponectin) in myocardial remodelling after ischaemic injury

    Histopathology

    (2003)
  • E.M. Tan et al.

    The 1982 revised criteria for the classification of systemic lupus erythematosus

    Arthritis Rheum

    (1982)
  • Cited by (60)

    • The impact of antimalarial agents on traditional and non-traditional subclinical atherosclerosis biomarkers in systemic lupus erythematosus: A systematic review and meta-analysis

      2021, Autoimmunity Reviews
      Citation Excerpt :

      Nineteen longitudinal [12,13,21–37] observational studies compared outcomes before and after AM therapy and forty-four cross-sectional studies [11,14,38–79] evaluated groups of patients with and without AM therapy. Eleven studies reported more than one AT marker [12,40,43,44,46,47,50,54,58,66,74]. Table 1 shows every CV biomarker evaluated in individual studies.

    • Cardiovascular disease in lupus

      2021, Lahita’s Systemic Lupus Erythematosus
    • A Correlational Study on Cerebral Microbleeds and Carotid Atherosclerosis in Patients with Ischemic Stroke

      2018, Journal of Stroke and Cerebrovascular Diseases
      Citation Excerpt :

      Some scholars believe that the pathogenesis of CMBs is associated with the increased permeability of the blood–brain barrier, and that endothelial dysfunction is one of the initiating factors.23 sE-selectin, a specific marker of vascular endothelium, is closely related to CMBs, and the expression of sE-selectin is upregulated when endothelial cells are damaged.24 Current animal experiments have shown that matrix metalloproteinase-9 (MMP-9) is closely associated with the destruction of the blood–brain barrier.25

    View all citing articles on Scopus
    View full text